Now showing items 1-13 of 13

  • Alpha-synuclein repeat variants and survival in parkinson's disease 

    Chung, S. J.; Biernacka, J. M.; Armasu, S. M.; Anderson, K.; Frigerio, R.; Aasly, J. O.; Annesi, G.; Bentivoglio, A. R.; Brighina, L.; Chartier-Harlin, M. C.; Goldwurm, S.; Hadjigeorgiou, G.; Jasinska-Myga, B.; Jeon, B. S.; Kim, Y. J.; Krüger, R.; Lesage, S.; Markopoulou, K.; Mellick, G.; Morrison, K. E.; Puschmann, A.; Tan, E. K.; Crosiers, D.; Theuns, J.; Van Broeckhoven, C.; Wirdefeldt, K.; Wszolek, Z. K.; Elbaz, A.; Maraganore, D. M.; Yahalom, G.; Orlev, Y.; Cohen, O. S.; Kozlova, E.; Friedman, E.; Inzelberg, R.; Hassin-Baer, S. (2014)
    Objectives: To determine whether α-synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods: Investigators from the Genetic Epidemiology of Parkinson's Disease ...
  • Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis 

    Vasilopoulos, Y.; Bagiatis, V.; Stamatopoulou, D.; Zisopoulos, D.; Alexiou, I.; Sarafidou, T.; Settas, L.; Sakkas, L.; Mamuris, Z. (2011)
    Objective: To investigate the possible influence of tumour necrosis factoralpha (TNF), TNF receptor I (TNFRI) and TNF receptor II (TNFRII) gene polymorphisms on anti-TNF treatment responsiveness, stratified by autoantibody ...
  • ASTRAL-R score predicts non-recanalisation after intravenous thrombolysis in acute ischaemic stroke 

    Vanacker, P.; Heldner, M. R.; Seiffge, D.; Mueller, H.; Eskandari, A.; Traenka, C.; Ntaios, G.; Mosimann, P. J.; Sztajzel, R.; Pereira, V. M.; Cras, P.; Engelter, S.; Lyrer, P.; Fischer, U.; Lambrou, D.; Arnold, M.; Michel, P. (2015)
    Intravenous thrombolysis (IVT) as treatment in acute ischaemic strokes may be insufficient to achieve recanalisation in certain patients. Predicting probability of non-recanalisation after IVT may have the potential to ...
  • Bloodstream infections and sepsis in Greece: Over-time change of epidemiology and impact of de-escalation on final outcome 

    Koupetori, M.; Retsas, T.; Antonakos, N.; Vlachogiannis, G.; Perdios, I.; Nathanail, C.; Makaritsis, K.; Papadopoulos, A.; Sinapidis, D.; Giamarellos-Bourboulis, E. J.; Pneumatikos, I.; Gogos, C.; Armaganidis, A.; Paramythiotou, E. (2014)
    Background: Choice of empirically prescribed antimicrobials for sepsis management depends on epidemiological factors. The epidemiology of sepsis in Greece was studied in two large-periods.Methods: Sepsis due to bloodstream ...
  • Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: A non-interventional, multicentre, post-marketing study 

    Anastassiou, E.; Iatrou, C. A.; Vlaikidis, N.; Vafiadou, M.; Stamatiou, G.; Plesia, E.; Lyras, L.; Vadalouca, A. (2011)
    Background and Objectives: Numerous controlled clinical trials have demonstrated the safety and efficacy of pregabalin in the treatment of neuropathic pain. The objectives of the present study were to assess the impact of ...
  • Kinetics of circulating immunoglobulin M in sepsis: Relationship with final outcome 

    Giamarellos-Bourboulis, E. J.; Apostolidou, E.; Lada, M.; Perdios, I.; Gatselis, N. K.; Tsangaris, I.; Georgitsi, M.; Bristianou, M.; Kanni, T.; Sereti, K.; Kyprianou, M. A.; Kotanidou, A.; Armaganidis, A. (2013)
    Introduction: The aim of this study was to investigate the kinetics of immunoglobulin M (IgM) during the different stages of sepsis. Methods: In this prospective multicenter study, blood sampling for IgM measurement was ...
  • Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology 

    Agorastos, T.; Chatzistamatiou, K.; Katsamagkas, T.; Koliopoulos, G.; Daponte, A.; Constantinidis, T.; Constantinidis, T. C. (2015)
    Objectives The objective of the present study is to assess the performance of a high-risk human papillomavirus (HR-HPV) DNA test with individual HPV-16/HPV-18 genotyping as a method for primary cervical cancer screening ...
  • Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis 

    Zachou, K.; Yurdaydin, C.; Drebber, U.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.; Zeuzem, S.; Bozkaya, H.; Schlaphoff, V.; Dienes, H. P.; Bock, T. C.; Manns, M. P.; Wedemeyer, H. (2010)
    Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ...
  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection 

    Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)
    Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ...
  • Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

    Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
    Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...
  • Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis 

    Syrogiannopoulos, G. A.; Bozdogan, B.; Grivea, I. N.; Ednie, L. M.; Kritikou, D. I.; Katopodis, G. D.; Beratis, N. G.; Appelbaum, P. C. (2004)
    Background: Short course antimicrobial therapy is suggested for group A streptococcal tonsillopharyngitis. Methods: The bacteriologic and clinical efficacies of clarithromycin [30 or 15 mg/kg/day twice daily (b.i.d.)] or ...
  • Uncommon leg ulcers in the lower extremity 

    Labropoulos, N.; Manalo, D.; Patel, N. P.; Tiongson, J.; Pryor, L.; Giannoukas, A. D. (2007)
    Objective: To determine the prevalence of uncommon ulcers, unrelated to venous or arterial etiology, in patients presenting to vascular clinics. Methods: This was a multicenter prospective study of consecutive patients ...
  • Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome 

    García-Borreguero, D.; Kohnen, R.; Högl, B.; Ferini-Strambi, L.; Hadjigeorgiou, G. M.; Hornyak, M.; de Weerd, A. W.; Happe, S.; Stiasny-Kolster, K.; Gschliesser, V.; Egatz, R.; Cabrero, B.; Frauscher, B.; Trenkwalder, C.; Hening, W. A.; Allen, R. P. (2007)
    Background: Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Its severity varies considerably from a minor ...